Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan

Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatini...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Jerry Shu-Hung Kuo, Cheng-Yu Chang, Shih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Subjects:	Afatinib Osimertinib EGFR mutation lung cancer rebiopsy
Online Access:	https://www.mdpi.com/1718-7729/32/1/36